The Profil Institute for Clinical Research, a clinical research organization (CRO) in Chula Vista, announced that Dr. Christian Weyer has joined the company as president and chief development officer.

Weyer joins Profil from Fate Therapeutics, where he recently served as president and CEO. Prior to Fate, Weyer held senior leadership positions at Amylin Pharmaceuticals where he contributed to the development and approval of several first-in-class medicines for diabetes and lipodystrophy. His background in diabetes and obesity will come in handy for work at the Profil Institute, which is focused on diabetes, obesity and fatty liver disease.

In the newly created role of chief development officer, Weyer will oversee the company’s clinical development services and new strategic partnerships.

Following training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany, Weyer worked at the National Institutes of Health conducting clinical research on the pathogenesis of obesity and type 2 diabetes. During his subsequent 12-year tenure with Amylin Pharmaceuticals, he held a number of senior leadership positions in R&D and corporate development, serving most recently as senior vice president of R&D, according to a Profil Institue news release. When Bristol-Myers Squibb bought Amylin in August 2012, Weyer joined Fate Therapeutics.

Dr. Marcus Hompesch will continue to lead Profil Institute as the company’s CEO and chairman of the board, according to the release.